Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. (2019)

First Author: Selinger C
Attributed to:  MRC Centre for Global Infectious Disease Analysis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.vaccine.2019.02.073

PubMed Identifier: 30890385

Publication URI: http://europepmc.org/abstract/MED/30890385

Type: Journal Article/Review

Volume: 37

Parent Publication: Vaccine

Issue: 16

ISSN: 0264-410X